Aigen Investment Management LP Buys 4,125 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Aigen Investment Management LP lifted its stake in Twist Bioscience Co. (NASDAQ:TWST) by 84.0% in the third quarter, HoldingsChannel.com reports. The fund owned 9,037 shares of the company’s stock after purchasing an additional 4,125 shares during the period. Aigen Investment Management LP’s holdings in Twist Bioscience were worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the 2nd quarter valued at approximately $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience during the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TWST. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird raised their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.22.

Insider Buying and Selling

In other Twist Bioscience news, Director Robert Chess sold 3,600 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the transaction, the director now owns 21,641 shares of the company’s stock, valued at $1,022,753.66. This represents a 14.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,118 shares of company stock valued at $4,391,151. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Down 8.3 %

NASDAQ TWST opened at $38.96 on Friday. Twist Bioscience Co. has a 52 week low of $18.80 and a 52 week high of $60.90. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -10.20 and a beta of 1.78. The company has a fifty day moving average of $43.90 and a two-hundred day moving average of $45.88.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.